Pathobiology of pulmonary hypertension. The role of platelets and thrombosis.

[1]  M. Humbert,et al.  Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension , 2000, Circulation.

[2]  M. Humbert,et al.  Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. , 2000, American journal of respiratory and critical care medicine.

[3]  M. Maclean,et al.  5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension , 2000, British journal of pharmacology.

[4]  G. Simonneau,et al.  Thrombotic risk factors in pulmonary hypertension. , 2000, The European respiratory journal.

[5]  M. Mcgoon,et al.  Obesity drugs and the heart. , 1999, Current problems in cardiology.

[6]  J. Findlay,et al.  Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  P. Dartevelle,et al.  Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  M. Humbert,et al.  Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study , 1999 .

[9]  K. Kerr,et al.  Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension. , 1999, Seminars in thoracic and cardiovascular surgery.

[10]  P. Flemming,et al.  Pulmonary Hypertension after Splenectomy? , 1999, Annals of Internal Medicine.

[11]  G. Garcia-Manero,et al.  Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases , 1999, American journal of hematology.

[12]  R. Wurtman,et al.  Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines , 1999, The Lancet.

[13]  M. Hoeper,et al.  Plasma coagulation profiles in patients with severe primary pulmonary hypertension. , 1998, The European respiratory journal.

[14]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[15]  R. Barst,et al.  Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. , 1997, Circulation.

[16]  H P Gurtner,et al.  The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. , 1997, Chest.

[17]  G. Simonneau,et al.  Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  B. Fanburg,et al.  A new role for an old molecule: serotonin as a mitogen. , 1997, The American journal of physiology.

[19]  M. Nakasato,et al.  Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. , 1997, The Tohoku journal of experimental medicine.

[20]  S. Harari,et al.  Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. , 1997, Thrombosis research.

[21]  R. Barst,et al.  Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. , 1997, American journal of respiratory and critical care medicine.

[22]  W. Klepetko,et al.  No Increased Prevalence of the Factor V Leiden Mutation in Chronic Major Vessel Thromboembolic Pulmonary Hypertension (CTEPH) , 1996, Thrombosis and Haemostasis.

[23]  R. Marlar,et al.  Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. , 1996, Chest.

[24]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[25]  J. Piette,et al.  Plasma levels of thrombomodulin in pulmonary hypertension. , 1996, The American journal of medicine.

[26]  J. Piette,et al.  High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. , 1996, The Journal of rheumatology.

[27]  A. Chaouat,et al.  The role of thrombosis in severe pulmonary hypertension. , 1996, The European respiratory journal.

[28]  J. Launay,et al.  Increased plasma serotonin in primary pulmonary hypertension. , 1995, The American journal of medicine.

[29]  G. Simonneau,et al.  Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension , 1995, Thrombosis and Haemostasis.

[30]  J. Golden,et al.  Do patients with primary pulmonary hypertension develop extensive central thrombi? , 1995, Circulation.

[31]  D. Loukopoulos,et al.  Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. , 1995, Chest.

[32]  C. Wagenvoort.  Pathology of pulmonary thromboembolism. , 1995, Chest.

[33]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease. , 1994, The American journal of cardiology.

[34]  A. Lopes,et al.  Circulating Platelet Aggregates Indicative of in Vivo Platelet Activation in Pulmonary Hypertension , 1993, Angiology.

[35]  P. Mulder,et al.  Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication? , 1993, Chest.

[36]  B. Binder,et al.  Endogenous Fibrinolytic System in Chronic Large‐Vessel Thromboembolic Pulmonary Hypertension , 1992, Circulation.

[37]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[38]  D. Rodman,et al.  Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. , 1991, The American journal of physiology.

[39]  E. van Marck,et al.  Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? , 1991, The European respiratory journal.

[40]  R. Abbate,et al.  Pulmonary hypertension associated with long-standing thrombocytosis. , 1991, Chest.

[41]  W. De Backer,et al.  Pulmonary hypertension and sickle hemoglobinopathy. , 1990, Chest.

[42]  J. Launay,et al.  Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. , 1990, The American journal of medicine.

[43]  W. Auger,et al.  Chronic major-vessel thromboembolic pulmonary hypertension. , 1990, Circulation.

[44]  R. Virmani,et al.  Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. , 1988, The American review of respiratory disease.

[45]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[46]  E. Orringer,et al.  Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. , 1982, The American journal of medicine.

[47]  A. Moss,et al.  Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. , 1972, The New England journal of medicine.

[48]  Wagenvoort Ca.  The pathology of primary pulmonary hypertension. , 1970 .